Compare CGC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGC | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.2M | 335.6M |
| IPO Year | 2023 | 1999 |
| Metric | CGC | AGEN |
|---|---|---|
| Price | $0.66 | $6.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.96 | ★ $26.33 |
| AVG Volume (30 Days) | ★ 2.2M | 986.1K |
| Earning Date | 11-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.17 | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | $12,759,000.00 | ★ $42,877,086.00 |
| Revenue This Year | $21.39 | $9.64 |
| Revenue Next Year | $8.33 | N/A |
| P/E Ratio | ★ N/A | $6.75 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $0.65 | $2.71 |
| 52 Week High | $2.38 | $10.19 |
| Indicator | CGC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 21.54 | 39.39 |
| Support Level | N/A | $6.34 |
| Resistance Level | $1.08 | $8.64 |
| Average True Range (ATR) | 0.04 | 0.45 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 6.86 | 16.47 |
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.